A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.
about
Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assayAcquired antibody responses against Plasmodium vivax infection vary with host genotype for duffy antigen receptor for chemokines (DARC)Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180Lineage-specific positive selection at the merozoite surface protein 1 (msp1) locus of Plasmodium vivax and related simian malaria parasites.Asymptomatic Plasmodium vivax infections induce robust IgG responses to multiple blood-stage proteins in a low-transmission region of western Thailand.Malaria in Brazil: an overview.Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysisEvaluation of the naturally acquired antibody immune response to the Pv200L N-terminal fragment of Plasmodium vivax merozoite surface protein-1 in four areas of the Amazon Region of Brazil.Polymorphism of the Pv200L fragment of merozoite surface protein-1 of Plasmodium vivax in clinical isolates from the Pacific coast of Colombia.B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon.Asymptomatic infection in individuals from the municipality of Barcelos (Brazilian Amazon) is not associated with the anti-Plasmodium falciparum glycosylphosphatidylinositol antibody response.Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individualsIn silico Identification and Validation of a Linear and Naturally Immunogenic B-Cell Epitope of the Plasmodium vivax Malaria Vaccine Candidate Merozoite Surface Protein-9Naturally Acquired Antibody Responses to Plasmodium vivax and Plasmodium falciparum Merozoite Surface Protein 1 (MSP1) C-Terminal 19 kDa Domains in an Area of Unstable Malaria Transmission in Southeast Asia.Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with Plasmodium vivax SporozoitesAntigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians.Genetic diversity among Plasmodium vivax isolates along the Thai-Myanmar border of ThailandAlterations of splenic architecture in malaria are induced independently of Toll-like receptors 2, 4, and 9 or MyD88 and may affect antibody affinityImmunogenetic markers associated with a naturally acquired humoral immune response against an N-terminal antigen of Plasmodium vivax merozoite surface protein 1 (PvMSP-1).Plasmodium vivax: who cares?Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children.Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children.High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms.Allele-specific antibodies to Plasmodium vivax merozoite surface protein-1: prevalence and inverse relationship to haemoglobin levels during infection.What Is Known about the Immune Response Induced by Plasmodium vivax Malaria Vaccine Candidates?A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection.Genetic diversity of MSP1 Block 2 of Plasmodium vivax isolates from Manaus (central Brazilian Amazon).Molecular markers and genetic diversity of Plasmodium vivax.N-terminal Plasmodium vivax merozoite surface protein-1, a potential subunit for malaria vivax vaccine.Insights into the naturally acquired immune response to Plasmodium vivax malaria.Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10.An immunomics approach for the analysis of natural antibody responses to Plasmodium vivax infection.Humoral immune responses to a recombinant Plasmodium vivax tryptophan-rich antigen among Plasmodium vivax-infected patients and its localization in the parasite.Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians.
P2860
Q28394065-2C30F3A2-F7EF-4D67-9574-A9A1FA170AE4Q28750566-911CCC0D-0546-4E74-AD4F-9F1FC6216281Q30044377-BE98476A-3475-4EBF-AC0F-2C892FA3388AQ33532314-81596191-899D-4632-9A17-B5894AC11618Q33617694-D68ABA9A-693D-4EB8-94D9-7428EBDFF0B3Q33939774-09CA8741-900B-41B6-B292-A84287FE69DAQ34234390-509A9BB9-25CE-46AB-AA49-3846A5262C7AQ34546246-FAB86366-C6C4-4CBF-A1C0-EF03936D28E4Q34546254-3E8FE8E4-C307-457E-A093-DC1B47A5E93DQ34726966-6E6A1A3C-581E-4AC6-86B3-BC5046B68313Q34987487-9581D2C1-472F-4467-9F7B-A16A32DB53E1Q35606249-9789B345-AD76-4FD4-BB16-8F7A9FB1DEDCQ35898819-90A04A26-3321-462F-A96C-4B2C0CDB74ECQ35964846-8A646044-BF56-498A-B611-EC5DCFB69920Q35970236-A20BE597-240F-4674-80D7-AA4EB5A9B76FQ36313424-89013EC5-23E1-4E52-BE6C-C6B90B394EB1Q36560648-96E46C03-CF1E-4925-8145-935A159D976AQ36845116-F51B7627-974F-4043-815A-E8A82D8B4F61Q36965601-48B3590A-C532-44FE-B505-D9D928875591Q37018632-DC89ABB5-8666-4509-ACA1-E1F9D9A4E823Q37308698-39040838-EA6A-4108-A3C2-C17EB760290DQ37333369-3A6E230E-A0D8-4685-926F-CAF2E8D998C1Q37352099-6F1999DD-2846-4123-85E6-9FD68014A1C5Q37419309-3BE934B4-5A73-4416-849F-5190CA260482Q37638131-F78E0A25-527A-4AA4-BB81-D2ED100A177FQ37685993-DAFA26B9-A1DA-4054-9AFD-2C7D34B769F4Q37704962-995A5884-6EB9-44B3-9AEF-40841912BB98Q37924602-78EB6B96-B61D-4D39-A3F1-82F16A7D650AQ38159694-D01C2309-A885-4134-BA11-8B4A2D7AB30CQ38728598-0BFC288A-7443-4ED7-A6A3-7DBF78D1FDD3Q38943177-283557B3-D559-466F-B2C2-34BE5A2E2EEDQ41150428-199255BE-9605-451E-93AE-8CE347B347EBQ41622508-982845C8-4048-496F-A53C-F2F3FE1EB582Q46926980-1BE69873-DC64-40B6-A25D-438B351B3F9A
P2860
A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A reduced risk of infection wi ...... f merozoite surface protein 1.
@en
A reduced risk of infection wi ...... f merozoite surface protein 1.
@nl
type
label
A reduced risk of infection wi ...... f merozoite surface protein 1.
@en
A reduced risk of infection wi ...... f merozoite surface protein 1.
@nl
prefLabel
A reduced risk of infection wi ...... f merozoite surface protein 1.
@en
A reduced risk of infection wi ...... f merozoite surface protein 1.
@nl
P2093
P2860
P921
P1476
A reduced risk of infection wi ...... f merozoite surface protein 1.
@en
P2093
Carmen Fernandez-Becerra
Fabiana Piovesan Alves
Hernando A del Portillo
Luiz Hildebrando Pereira da Silva
Neida Rodrigues Santos
Oliver Pein
Paulo Afonso Nogueira
P2860
P304
P356
10.1128/IAI.74.5.2726-2733.2006
P407
P577
2006-05-01T00:00:00Z